Micromet's cancer drug portfolio draws big drugmakers' attention

06/14/2010 | Bloomberg Businessweek

Biotech firm Micromet was able to secure a partnership with major drugmakers, including Bayer and Boehringer Ingelheim, because of its line of cancer treatments that might boost the effectiveness of rival medicines. Blinatumomab, Micromet's drug candidate for acute lymphocytic leukemia, led to complete remission during a clinical trial in about 80% of patients who still had leukemia cells after undergoing different forms of chemotherapy.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID